Body weight-adjusted Uptravi (selexipag) dosing for children and adolescents with pulmonary arterial hypertension (PAH) resulted in exposure to the treatment’s active ingredient comparable to that in ...
The U.S. Food and Drug Administration (FDA) has provided Tiakis Biotech with advice for a planned Phase 2 clinical trial testing tiprelestat for pulmonary arterial hypertension (PAH). The ATHENA trial ...
Are you managing chronic pain alongside pulmonary hypertension (PH)? Did it disrupt your holiday plans? If you answered yes, you’re not alone. Many folks in the PH and broader rare disease communities ...